Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice

The matrix metalloproteinase (MMP) family (approximately 25 members in mammals) has been implicated in extracellular matrix remodeling associated with embryonic development, cancer formation and progression, and various other physiological and pathological events. Inactivating mutations in individua...

Full description

Saved in:
Bibliographic Details
Published in:Oncogene Vol. 23; no. 29; pp. 5041 - 5048
Main Authors: JUNSEO OH, TAKAHASHI, Rei, ITOH, Takeshi, ITOHARA, Shigeyoshi, TAKAHASHI, Chiaki, NODA, Makoto, ADACHI, Eijiro, KONDO, Shunya, KURATOMI, Shinobu, NOMA, Akinori, ALEXANDER, David B, MOTODA, Hirotoshi, OKADA, Akiko, SEIKI, Motoharu
Format: Journal Article
Language:English
Published: Basingstoke Nature Publishing 24-06-2004
Nature Publishing Group
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The matrix metalloproteinase (MMP) family (approximately 25 members in mammals) has been implicated in extracellular matrix remodeling associated with embryonic development, cancer formation and progression, and various other physiological and pathological events. Inactivating mutations in individual matrix metalloproteinase genes in mice described so far, however, are nonlethal at least up to the first few weeks after birth, suggesting functional redundancy among MMP family members. Here, we report that mice lacking two MMPs, MMP-2 (nonmembrane type) and MT1-MMP (membrane type), die immediately after birth with respiratory failure, abnormal blood vessels, and immature muscle fibers reminiscent of central core disease. In the absence of MMP-2 and MT1-MMP, myoblast fusion in vitro is also significantly retarded. These findings suggest functional overlap in mice between the two MMPs with distinct molecular natures.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0950-9232
1476-5594
DOI:10.1038/sj.onc.1207688